<DOC>
	<DOCNO>NCT00392353</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose vorinostat azacitidine see well work treat patient myelodysplastic syndrome acute myeloid leukemia . Vorinostat may stop growth cancer abnormal cell block enzymes need cell growth . Drugs use chemotherapy , azacitidine , work different way stop growth cancer abnormal cell , either kill cell , stop dividing , stop spread . Giving vorinostat together azacitidine may kill cancer abnormal cell .</brief_summary>
	<brief_title>Vorinostat Azacitidine Treating Patients With Myelodysplastic Syndromes Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate safety toxicity vorinostat combination azacitidine patient myelodysplastic syndrome ( MDS ) select patient acute myeloid leukemia ( AML ) ( step 1 ) . II . To identify dos vorinostat azacitidine safe combination 2 agent administer repetitive cycle time use phase II study . III . To determine response rate patient treat combination suberoylanilide hydroxamic acid ( SAHA ) ( vorinostat ) azacitidine dos establish safe effective Step 1 expand cohort patient MDS . IV . To obtain preliminary data effect treatment combination vorinostat Aza C ( azacitidine ) patient MDS series biologic surrogate marker include : deoxyribonucleic acid ( DNA ) methylation specific gene ( e.g . p15 ) ; histone acetylation ; hematopoietic progenitor growth differentiation ; fate MDS clone change gene expression array profile . SECONDARY OBJECTIVES : I . Determine effect treatment combination time response , time leukemic transformation frequency transformation leukemia patient MDS phase II segment study . OUTLINE : This phase I , dose-escalation study follow phase II study . Patients receive azacitidine subcutaneously ( SC ) daily ( QD ) day 1-7 vorinostat orally ( PO ) 2-3 time daily day 3-5 , 3-9 , 3-16 . Treatment repeat every 28 day least 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow monthly 6 month every 2 month thereafter .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Eligibility Criteria phase I portion ( step 1 ) ; patient must diagnosis either MDS accord FrenchAmericanBritish ( FAB ) International Prognostic Scoring System ( IPSS ) criterion , diagnosis AML accord FAB World Health Organization ( WHO ) criterion MDS : All patient must establish diagnosis myelodysplastic syndrome confirm peripheral blood bone marrow maturational abnormality erythroid , megakaryocytic granulocytic series , define accord French AmericanBritish ( F.A.B . ) classification Refractory anemia ( RA ) , define anemia = &lt; 1 % blast peripheral blood dyserythropoiesis ; neutropenia thrombocytopenia may also present less common ; bone marrow usually normocellular hypercellular &lt; 5 % blast cell Refractory anemia ring sideroblast ( RARS ) , define refractory anemia , also include presence ring sideroblast comprise &gt; = 15 % nucleated cell bone marrow Refractory anemia excess blast ( RAEB ) , define 520 % myeloblast bone marrow le 5 % blast peripheral blood , together abnormality erythroid megakaryocytic granulocytic maturation consistent myelodysplasia Refractory anemia excess blast transformation ( RAEBT ) , defined 2129 % myeloblast marrow , 5 % blast peripheral blood , Auer rods granulocytic precursor marrow blood ( &lt; 30 % myeloblast marrow ) Chronic myelomonocytic leukemia ( CMMoL ) define absolute monocytosis ( &gt; 1 x 10^9/liter ) &lt; 5 % blast peripheral blood &lt; 20 % blast bone marrow ; additional criterion include white blood cell ( WBC ) = &lt; 13 x 10^9/L For patient refractory anemia refractory anemia ring sideroblast IPSS = &lt; 0.5 , must also meet least one follow criterion eligible : Symptomatic anemia require pack red blood cell ( PRBC ) transfusion least 3 month prior study entry ( document ) , Thrombocytopenia platelet count = &lt; 50,000/ml significant clinical hemorrhage ( e.g. , gastrointestinal [ GI ] , gastric ulcer [ GU ] gynecologic [ GYN ] hemorrhage require platelet transfusion ; petechia alone constitute sufficient hemorrhage ) Neutropenia absolute neutrophil count &lt; 1000/ul infection require treatment antibiotic Patients MDS classify accord IPSS criterion intermediate 1 , intermediate 2 high risk disease eligible Patients low risk MDS ( IPSS Score &lt; 0.5 ) must additionally meet criterion outline patient refractory anemia refractory anemia ring sideroblast AML phase 1 ; patient AML eligible phase II ; patient AML define accord FAB WHO criteria eligible phase I portion study ( phase 1 ) ; additional selection criterion : De novo AML AML evolve MDS associated intermediate poor risk cytogenetics patient decline standard chemotherapy fail relapse follow one prior regimen Additionally , patient 's disease must stable i.e . WBC = &lt; 25 x 10^9/L exhibit stable WBC require intervention WBC control hydroxyurea , chemotherapy leukophoresis &gt; 4 week No corticosteroid , interferon retinoids within one month prior study No treatment granulocyte colonystimulating factor ( GCSF ) , granulocytemacrophage colonystimulating factor ( GMCSF ) , hematopoietic growth factor , e.g . erythropoietin within one month prior study No prior treatment azacitidine , decitabine vorinostat Patients take valproic acid , histone deacetylase inhibitor , least 2 week prior enrollment Patients may treat investigational agent 28 day prior study entry must recover side effect Patients previously treat cancer leukemia chemotherapy radiation therapy may eligible ; may receive radiation chemotherapy within past 12 month must free evidence malignancy past 3 year ; patient prior history leukemia relapse MDS ineligible Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 ( Karnofsky &gt; = 60 % ) Life expectancy great 2 month Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) ; unless patient active hemolysis , elevation secondary ineffective erythropoiesis Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 X institutional ULN Creatinine within normal institutional limit OR creatinine clearance &gt; = 60 mL/min/1.73 m^2 patient creatinine level institutional normal Treatment must begin within 2 4 week complete prestudy test Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document Patients chemotherapy radiotherapy within 12 month prior enter study another malignancy evidence malignancy 3 year prior study entry Patients may receive investigational agent Patients may central nervous system ( CNS ) involvement MDS AML History allergic reaction attribute compound similar chemical biologic composition vorinostat agent use study Pregnant woman exclude study ; breastfeed discontinue mother treated vorinostat Any serious medical psychiatric illness would limit survival &lt; 3 month prevent grant informed consent Uncontrolled severe congestive heart failure ; ( include patient high output congestive heart failure [ CHF ] state secondary anemia control ) &gt; = 30 % myeloblast bone marrow M6 leukemia define FAB criterion ( phase II component study ) Prior treatment GCSF , GMCSF , hematopoietic growth factor , erythropoietin within one month prior study ; interferon retinoids within one month prior study Known positive serology human immunodeficiency virus ( HIV ) ; appropriate study undertake patient receive combination antiretroviral therapy indicate Active systemic bacterial , fungal viral infection ; infection fully treat patient afebrile 7 day study entry Prior history leukemia ( step 2 phase II component study ) Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , clinically significant cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Patients advance hepatic tumor exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>